GSTDTAP

浏览/检索结果: 共5条,第1-5条 帮助

已选(0)清除 条数/页:   排序方式:
Mutations in colon cancer match bacterial signature 期刊论文
NATURE, 2020, 580 (7802)
作者:  Gray, Alison C.
收藏  |  浏览/下载:15/0  |  提交时间:2020/07/03

Studies have pointed to a link between colon cancer and a gut bacterium that produces DNA-damaging molecules. The discovery of a mutational signature linked to these bacteria in human colon cancer supports this association.


  
Mechanisms and therapeutic implications of hypermutation in gliomas 期刊论文
NATURE, 2020, 580 (7804) : 517-+
作者:  Feng, Kaibo;  Quevedo, Raundi E.;  Kohrt, Jeffrey T.;  Oderinde, Martins S.;  Reilly, Usa;  White, M. Christina
收藏  |  浏览/下载:42/0  |  提交时间:2020/07/03

A high tumour mutational burden (hypermutation) is observed in some gliomas(1-5)  however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the molecular determinants of mutational burden and signatures in 10,294 gliomas. We delineate two main pathways to hypermutation: a de novo pathway associated with constitutional defects in DNA polymerase and mismatch repair (MMR) genes, and a more common post-treatment pathway, associated with acquired resistance driven by MMR defects in chemotherapy-sensitive gliomas that recur after treatment with the chemotherapy drug temozolomide. Experimentally, the mutational signature of post-treatment hypermutated gliomas was recapitulated by temozolomide-induced damage in cells with MMR deficiency. MMR-deficient gliomas were characterized by a lack of prominent T cell infiltrates, extensive intratumoral heterogeneity, poor patient survival and a low rate of response to PD-1 blockade. Moreover, although bulk analyses did not detect microsatellite instability in MMR-deficient gliomas, single-cell whole-genome sequencing analysis of post-treatment hypermutated glioma cells identified microsatellite mutations. These results show that chemotherapy can drive the acquisition of hypermutated populations without promoting a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in cancer.


Temozolomide therapy seems to lead to mismatch repair deficiency and hypermutation in gliomas, but not to an increase in response to immunotherapy.


  
Mutational signature in colorectal cancer caused by genotoxic pks(+)E. coli 期刊论文
NATURE, 2020, 580 (7802) : 269-+
作者:  Lin, Xi;  Li, Mingyue;  Wang, Niandong;  Wu, Yiran;  Luo, Zhipu;  Guo, Shimeng;  Han, Gye-Won;  Li, Shaobai;  Yue, Yang;  Wei, Xiaohu;  Xie, Xin;  Chen, Yong;  Zhao, Suwen;  Wu, Jian;  Lei, Ming;  Xu, Fei
收藏  |  浏览/下载:38/0  |  提交时间:2020/07/03

Various species of the intestinal microbiota have been associated with the development of colorectal cancer(1,2), but it has not been demonstrated that bacteria have a direct role in the occurrence of oncogenic mutations. Escherichia coli can carry the pathogenicity island pks, which encodes a set of enzymes that synthesize colibactin(3). This compound is believed to alkylate DNA on adenine residues(4,5) and induces double-strand breaks in cultured cells(3). Here we expose human intestinal organoids to genotoxic pks(+)E. coli by repeated luminal injection over five months. Whole-genome sequencing of clonal organoids before and after this exposure revealed a distinct mutational signature that was absent from organoids injected with isogenic pks-mutant bacteria. The same mutational signature was detected in a subset of 5,876 human cancer genomes from two independent cohorts, predominantly in colorectal cancer. Our study describes a distinct mutational signature in colorectal cancer and implies that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin-producing pks pathogenicity island.


Organoids derived from human intestinal cells that are co-cultured with bacteria carrying the genotoxic pks(+) island develop a distinct mutational signature associated with colorectal cancer.


  
Microbial Community Composition in Deep-Subsurface Reservoir Fluids Reveals Natural Interwell Connectivity 期刊论文
WATER RESOURCES RESEARCH, 2020, 56 (2)
作者:  Zhang, Yuran;  Dekas, Anne E.;  Hawkins, Adam J.;  Parada, Alma E.;  Gorbatenko, Oxana;  Li, Kewen;  Horne, Roland N.
收藏  |  浏览/下载:21/0  |  提交时间:2020/07/02
interwell connectivity  microbial community  high-throughput DNA sequencing  deep subsurface  fracture characterization  DNA signature  
The repertoire of mutational signatures in human cancer 期刊论文
NATURE, 2020, 578 (7793) : 94-+
作者:  Ciurlo, Anna;  39;Neil, Kelly Kosmo
收藏  |  浏览/下载:18/0  |  提交时间:2020/07/03

Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature(1). Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium(2) of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses(3-15), enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated-but distinct-DNA damage, repair and/or replication mechanisms. By estimating the contribution of each signature to the mutational catalogues of individual cancer genomes, we revealed associations of signatures to exogenous or endogenous exposures, as well as to defective DNA-maintenance processes. However, many signatures are of unknown cause. This analysis provides a systematic perspective on the repertoire of mutational processes that contribute to the development of human cancer.